USFDA places clinical hold on Gilead Sciences trials testing HIV pill combination
Foster City: Gilead Sciences has announced that the U.S. Food and Drug Administration has placed a clinical hold on its HIV treatment trials of GS-1720 (an investigational integrase strand transfer inhibitor) and/or GS-4182 (an investigational capsid inhibitor).
The clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182.
Clinical trial investigators involved in the trials have been informed of these actions. GS-1720 and GS-4182 are investigational agents and have not been approved anywhere globally.
"We intend to investigate and pursue the potential of both agents and are committed to working with regulatory authorities to resolve the issues underlying the clinical hold," Gilead stated.
Gilead has multiple other long-acting oral and injectable investigational HIV treatment combinations under evaluation in clinical and preclinical studies, including combinations with weekly, monthly, quarterly, and twice-yearly dosing. This hold does not impact these combinations or their respective clinical or pre-clinical development programs.
The safety of individuals taking Gilead medicines is our foremost priority and we remain focused on pursuing advances to improve outcomes and expand options for people living with HIV.
The following studies have been placed on clinical hold:
Protocol Number | Phase | Protocol Title |
GS-US-695-6509 WONDERS-1 | Phase 2/3 (NCT06544733) | An Operationally Seamless Phase 2/3, Randomized, Active - Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1 |
GS-US-695-7156 WONDERS-2 | Phase 2/3 (NCT06613685) | An Operationally Seamless Phase 2/3, Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Treatment-Naive People With HIV-1 |
Three additional Phase 1 trials of either agent and/or their combinations are also on hold.
Gilead Sciences, Inc. is a biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.